ClinicalTrials.gg
Active, not recruitingNCT06920901Updated Oct 13, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

A Phase 1 interventional study of APG777 and Placebo in Asthma, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Asthma by AbbVie — none open to participants now, 1 under way, none of them phase 3. Asthma · AbbVie.

Enrollment
7th of 11
31 · median 32
Started
2025
the only one that year
Phase 1
3 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Asthma by AbbVie, this one is the 7th largest by enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 11 studies in Asthma by AbbVie is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Asthma by AbbVie as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.

The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Mild to moderate asthma
  • Tolerability
  • Immunogenicity
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of mild-to-moderate asthma (Global Initiative for Asthma 2023 criteria) ≥ 1 year prior to Screening
  • Maintain FeNO-high (≥ 25 parts per billion [ppb]) or FeNO-low (\< 25 ppb) status from Screening to Day 1 prior to Randomization
  • Pre-bronchodilator (FEV1) ≥ 60% of predicted normal value at Screening
  • Asthma Control Test (ACT) score > 19 at Screening
  • Maintained control on as-needed short-acting beta-agonist (SABA) +/- stable dose inhaled (ICS) or stable dose of ICS/ long-acting beta-agonist (LABA); +/- stable dose leukotriene receptor antagonist (LTRA). ICS dose should be stable for ≥ 12 weeks prior to Day 1, LTRA dose should be stable for ≥ 8 weeks prior to Day 1
  • Women of and male participants to use a highly effective form of

Exclusion criteria

Exclusion Criteria:

  • Any asthma exacerbation requiring systemic within 12 weeks of Screening and/or any asthma exacerbation that resulted in overnight hospitalization within 6 months prior to Screening
  • Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia
  • History of biologics use for treatment or control of asthma
  • Current smokers or participants with a smoking history of ≥ 10 pack years
  • Known history of illicit drug abuse, harmful alcohol use

Note: Other protocol defined criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    APG777

    Participants will receive protocol specified dose of APG7777

    Drug: APG777

  • Placebo comparator
    Placebo

    Participants will receive matching placebo

    Drug: Placebo

Interventions

  • DrugAPG777

    APG777 subcutaneous injection

  • DrugPlacebo

    Matching placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 52 weeks

  2. Number of Participants with Abnormal Laboratory Findings

    Time frame: Up to 52 weeks

  3. Number of Participants with Abnormal Vital Signs

    Time frame: Up to 52 weeks

  4. Number of Participants with Abnormal Electrocardiograms (ECGs)

    Time frame: Up to 52 weeks

  5. Number of Participants with Abnormal Physical Examination Findings

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Maximum concentration (Cmax) of APG777

    Time frame: Up to 48 weeks

  2. Time to reach Cmax (tmax)

    Time frame: Up to 48 weeks

  3. Terminal elimination rate constant (λz)

    Time frame: Up to 48 weeks

  4. Terminal Elimination half-life (t1/2)

    Time frame: Up to 48 weeks

  5. Area Under the Serum Concentration-time curve (AUC) from Time 0 to the Last Quantifiable Time Point (AUC0-last)

    Time frame: Up to 48 weeks

  6. AUC From Time 0 Extrapolated to Infinity (AUC0-inf)

    Time frame: Up to 48 weeks

  7. Apparent Clearance of APG777 (CL/F)

    Time frame: Up to 48 weeks

  8. Apparent Volume of Distribution (Vz/F)

    Time frame: Up to 48 weeks

  9. Number of Participants with Anti-Drug-Antibodies (ADAs)

    Time frame: Up to 48 weeks

  10. Cmax in Participants With and without ADAs

    Time frame: Up to 48 weeks

  11. AUClast Participants With and without ADAs

    Time frame: Up to 48 weeks

  12. AUCInf Participants With and without ADAs

    Time frame: Up to 48 weeks

07

Study locations

11 sites
  • Investigational Site
    La Jolla, California 92037, United States
  • Investigational Site
    Long Beach, California 90808, United States
  • Investigational Site
    San Jose, California 95117, United States
  • Investigational Site
    Torrance, California 90505, United States
  • Investigational Site
    Normal, Illinois 61761, United States
  • Investigational Site
    Kansas City, Missouri 66160, United States
  • Investigational Site
    Edmond, Oklahoma 73034, United States
  • Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • Investigational Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Investigational Site
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Publications

  • Lim XQ, Winter E, Nograles K, Xu J, Zhang ZQ, Thankamony S, Dillinger L, Dambkowski CL. A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers. Clin Transl Sci. 2025 Dec;18(12):e70456. doi: 10.1111/cts.70456. PubMed 41422501 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2026, 17 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 17 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 10, 2025
StartActual
Mar 27, 2025
Primary completionActual
Sep 17, 2026
CompletionEst.
Mar 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06920901
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 27, 2025
Primary completion
Sep 17, 2026
Completion
Mar 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zumilokibart

Start the discussion